Monoclonal antibody designed for SARS-nCoV-2 spike protein of receptor binding domain on antigenic targeted epitopes for inhibition to prevent viral entryArticle Published on 2023-04-012023-07-09 Journal: Molecular diversity [Category] COVID19(2023년), [키워드] cellular immune responses COVID19 Human receptor angiotensin converting enzyme-2 (hACE2) monoclonal antibody receptor binding domain (RBD) Severe acute respiratory syndrome-coronavirus (SARS-CoV-2) spike (S) protein. [DOI] 10.1007/s11030-022-10449-x PMC 바로가기
Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model마우스 모델에서 SARS-CoV-2 공격에 대한 보호 반응 유도에 대한 최적화된 서열과 SARS-CoV-2의 스파이크 단백질 야생형 DNA 서열의 비교Article Published on 2022-12-312022-09-11 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 비임상, 진단, [키워드] acid Against Antiviral binding breath CD4 CD8+ cellular immune responses cellular immunity challenge clinical trial contributing to COVID-19 CTL demonstrated DNA DNA vaccine expression full-length spike protein hACE2 humoral humoral and cellular immunity IFN-γ immune immune responses immunogen in vitro induction mice Model mouse Neutralizing antibodies optimization optimizations pGX-9501 platform Protective Protective effects protective response RBD binding response robust SARS-CoV-2 sequence spike Spike protein subsequent T cell T cells the vaccine Transgenic mouse Type virus wild-type wild-type sequence. [DOI] 10.1080/21645515.2021.2016201 PMC 바로가기 [Article Type] Article
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 VariantsArticle Published on 2022-10-262022-11-15 Journal: Microbiology Spectrum [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome antibody AZD1222 booster vaccination cellular Cellular immune response cellular immune responses cellular immunity coronavirus COVID-19 Delta delta variant dose effective elevated elicit Emergency use authorization emerging variants evaluated Evidence Heterologous heterologous prime-boost heterologous vaccination humoral immune immune evasion immune response immune responses IMPROVE increase in induce Infection interferon mRNA mRNA vaccine mRNA-1273 Multiple Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody omicron Prevent priming promote Protein subunit protein subunit vaccine provided RBD Receptor binding domain reduced regimen response SARS-CoV-2 SARS-CoV-2 variants significantly subunit suggested T cell Taiwan vaccination vaccination schedule Vaccine variant variants Viral variants Viral variants. wild type [DOI] 10.1128/spectrum.00609-22 PMC 바로가기
Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritisArticle Published on 2022-10-122022-11-15 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료제, [키워드] addition age anti-CD20 therapy anti-S anti-S antibody anti-SARS-CoV-2 antibodies antibody Antibody Response BNT162b2 cell-mediated response Cellular immune response cellular immune responses ChAdOx1 Concentration Corona covariate adjustment COVID-19 COVID-19 vaccine declined dependent on DMARD (disease-modifying antirheumatic drug treatment) domains dose enrolled Factor healthy controls humoral IL-6 inhibitor immune response Infection inhibited investigated IQR magnitude median time mRNA-1273 Patient patients patients treated peptides positive patient reduced respiratory rheumatoid arthritis RNA RNA vaccine SARS-CoV-2 significant effect significantly Specific specific antibodies specific antibody subject T-cell T-cell Response targeted therapy the healthy the interferon the SARS-CoV-2 the vaccine therapy vaccination vaccination. Vaccine variables was measured were infected [DOI] 10.3389/fimmu.2022.960001 PMC 바로가기
Intranasal immunization with recombinant Vaccinia virus encoding trimeric SARS-CoV-2 spike receptor-binding domain induces neutralizing antibodyArticle Published on 2022-09-222022-11-15 Journal: Vaccine [Category] SARS, 진단, 치료기술, [키워드] BALB/c mice Bronchoalveolar lavage fluid cellular immune responses COVID-19 detectable dissemination domain Effects elicited evaluated exhibited expressing humoral IgA IgG immune response immunization immunized induce Infection intranasal Lymphocytes mice mucosal mucosal immune nasal washe neutralization neutralization activities Neutralizing Neutralizing antibodies neutralizing antibody RBD respiratory response robust SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 spike protein secretory IgA sera systemic immune response transmission of SARS-CoV-2 trimeric trimeric RBD Vaccine vaccinia vaccinia virus. virus [DOI] 10.1016/j.vaccine.2022.08.054 PMC 바로가기
Effectiveness of Booster Doses of the SARS-CoV-2 Inactivated Vaccine KCONVAC against the Mutant StrainsArticle Published on 2022-09-122022-11-15 Journal: Viruses [Category] SARS, 변종, 진단, 치료기술, [키워드] addition B.1.1.529 B.1.1.7 B.1.351 B.1.617.2 Beta boost booster CD8 T cell CD8 T-cell cellular Cellular immune response cellular immune responses cellular immunity convalescent COVID-19 epidemic Delta Effectiveness Efficiency High-dose humoral immune inactivated Inactivated vaccine inactivated vaccine KCONVAC injection neutralizing antibody omicron reached recognize SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 variants several variants strain the SARS-CoV-2 vaccination variant variants variants. was selected [DOI] 10.3390/v14092016 PMC 바로가기
Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trialArticle Published on 2022-09-122022-11-15 Journal: Nature Communications [Category] SARS, 진단, [키워드] 1:1 age Analysis antibody blinded BNT162b2 booster vaccination cellular immune responses ChAdOx1 nCoV-19 clinical trial COVID-19 COVID-19 vaccination determine dose Endpoint EudraCT Heterologous homologous Immunosuppressed immunosuppressed patients Impaired include mRNA mRNA vaccination mRNA vaccine mRNA-1273 multivariable logistic regression outcome Patient performed Randomized Randomized controlled trial receive reduced SARS-CoV-2 spike SARS-CoV-2-specific T-cell response secondary Serious Adverse Event Seroconversion seroconversion rate seroconvert significantly higher single center Support vaccination Vaccination strategy Vaccine vaccine group [DOI] 10.1038/s41467-022-33036-y PMC 바로가기
Adipokines, and not vitamin D, associate with antibody immune responses following dual BNT162b2 vaccination within individuals younger than 60 yearsArticle Published on 2022-09-022022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] acute respiratory syndrome adiponectin age antibody antibody immune responses. Antibody Response antibody titres Biomarker BNT162b2 BNT162b2 vaccination caused cellular immune responses changes in Coronavirus-2 COVID-19 pandemic CRP Efficacy Evidence Factor Health immune response immune responses IMPROVE increase in individual individuals Infection investigated MCP-1 mortality rate natural infection outbreak PAI-1 pro-inflammatory molecule recent reducing SARS-CoV-2 searched severity of COVID-19 the antibody response vaccination Vaccine vitamin D serum [DOI] 10.3389/fimmu.2022.1000006 PMC 바로가기
A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipientsBNT162b2 mRNA 백신의 세 번째 접종은 간 이식 환자의 면역 반응을 크게 향상시킵니다Article Published on 2022-09-012022-09-12 Journal: Journal of hepatology [Category] Fulltext, MERS, 진단, [키워드] Adverse adverse effect adverse effects age Anti-RBD IgG anti-SARS-CoV-2 antibody Antibody Response binding domain BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine Booster vaccine cellular immune responses cellular response center correlated determine dose doses Effect evaluate evaluated Factor fatigue Follow-up geometric humoral humoral immune response IgG immune immune response Immunity Immunosuppression immunosuppressive medications IMPROVE inhibitor liver liver transplant recipients local pain majority male median age Mild monotherapy neutralizing antibody Older age Patient predict RBD recipient recipients reported response Side effect side effects BNT162b2 mRNA vaccine significantly solid organ transplant T-cell the patient third dose. Treatment Vaccine vaccine dose [DOI] 10.1016/j.jhep.2022.03.042 PMC 바로가기 [Article Type] Article
Immunogenicity and efficacy of Ad26.COV2.S: An adenoviral vector-based COVID-19 vaccineArticle Published on 2022-09-012022-11-15 Journal: Immunological reviews [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome Ad26.COV2.S Ad26.COV2.S vaccine Adenovirus antibodies booster booster vaccination caused cellular immune responses coronavirus coronavirus disease COVID-19 COVID-19 pandemic COVID-19 vaccine death Efficacy effort elicit elicited full-length functional Heterologous homologous or heterologous Hospitalization humoral humoral immune response immunogenicity increase individual membrane-bound mitigate moderate morbidity and mortality mRNA pandemic postvaccination Protective reduced regimen SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variants sensitivity Spike protein vaccination Vaccine vaccine. Vaccines variant [DOI] 10.1111/imr.13088 PMC 바로가기